Merus: Merus N.V.: Merus Announces Abstract Accepted for Presentation at the 2025 ASCO Annual Meeting

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ...